A detailed history of Price T Rowe Associates Inc transactions in Novavax Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 56,065 shares of NVAX stock, worth $776,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,065
Previous 47,937 16.96%
Holding current value
$776,500
Previous $231,000 16.45%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.76 - $6.02 $30,561 - $48,930
8,128 Added 16.96%
56,065 $269,000
Q4 2023

Feb 14, 2024

SELL
$4.8 - $7.67 $25,238 - $40,328
-5,258 Reduced 9.88%
47,937 $231,000
Q3 2023

Nov 14, 2023

BUY
$6.81 - $9.74 $1,375 - $1,967
202 Added 0.38%
53,195 $386,000
Q2 2023

Aug 14, 2023

SELL
$6.67 - $9.52 $32,269 - $46,057
-4,838 Reduced 8.37%
52,993 $394,000
Q1 2023

May 15, 2023

BUY
$5.76 - $12.48 $67,351 - $145,928
11,693 Added 25.34%
57,831 $401,000
Q4 2022

Feb 14, 2023

BUY
$8.86 - $25.04 $4,917 - $13,897
555 Added 1.22%
46,138 $474,000
Q3 2022

Nov 14, 2022

BUY
$18.2 - $76.12 $45,008 - $188,244
2,473 Added 5.74%
45,583 $830,000
Q2 2022

Aug 15, 2022

SELL
$36.28 - $75.29 $42,338 - $87,863
-1,167 Reduced 2.64%
43,110 $2.22 Million
Q1 2022

May 16, 2022

SELL
$69.73 - $142.9 $12.1 Million - $24.7 Million
-173,080 Reduced 79.63%
44,277 $3.26 Million
Q4 2021

Feb 14, 2022

SELL
$134.56 - $217.97 $33.4 Million - $54.2 Million
-248,562 Reduced 53.35%
217,357 $31.1 Million
Q3 2021

Nov 15, 2021

BUY
$177.8 - $270.58 $13.5 Million - $20.6 Million
76,195 Added 19.55%
465,919 $96.6 Million
Q2 2021

Aug 16, 2021

SELL
$121.0 - $257.67 $52.4 Million - $112 Million
-433,044 Reduced 52.63%
389,724 $82.7 Million
Q1 2021

May 17, 2021

BUY
$112.98 - $319.93 $53.9 Million - $153 Million
476,750 Added 137.78%
822,768 $149 Million
Q4 2020

Feb 16, 2021

BUY
$78.74 - $139.5 $27.2 Million - $48.3 Million
346,018 New
346,018 $38.6 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $1.08B
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.